ZA888978B - Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension - Google Patents

Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension

Info

Publication number
ZA888978B
ZA888978B ZA888978A ZA888978A ZA888978B ZA 888978 B ZA888978 B ZA 888978B ZA 888978 A ZA888978 A ZA 888978A ZA 888978 A ZA888978 A ZA 888978A ZA 888978 B ZA888978 B ZA 888978B
Authority
ZA
South Africa
Prior art keywords
interleukin
carboxylterminal
immobilized
extension
immobilized interleukin
Prior art date
Application number
ZA888978A
Other languages
English (en)
Inventor
Yuan Lin De Vries
Lin De Vries Yuan
Richard John Robb
John Robb Richard
Paul Simon
Simon Paul
Charles Thayer White
Thayer White Charles
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of ZA888978B publication Critical patent/ZA888978B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA888978A 1987-12-04 1988-11-30 Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension ZA888978B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12893187A 1987-12-04 1987-12-04

Publications (1)

Publication Number Publication Date
ZA888978B true ZA888978B (en) 1990-07-25

Family

ID=22437677

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA888978A ZA888978B (en) 1987-12-04 1988-11-30 Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension

Country Status (11)

Country Link
EP (1) EP0319012A3 (de)
JP (1) JPH02300A (de)
KR (1) KR890009978A (de)
AU (1) AU2635088A (de)
DK (1) DK673788A (de)
FI (1) FI885628A7 (de)
HU (1) HUT50506A (de)
IL (1) IL88565A0 (de)
NO (1) NO885389L (de)
PT (1) PT89121A (de)
ZA (1) ZA888978B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229272A (en) * 1989-04-25 1993-07-20 Igen, Inc. Catalytic antibody components
WO1990009798A1 (en) * 1989-02-24 1990-09-07 Immunotherapeutics, Inc. Immobilized cytokines
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6919211B1 (en) 1989-06-07 2005-07-19 Affymetrix, Inc. Polypeptide arrays
US6955915B2 (en) 1989-06-07 2005-10-18 Affymetrix, Inc. Apparatus comprising polymers
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
DE69019609T2 (de) * 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
FR2653020B1 (fr) * 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
WO1992000762A1 (en) * 1990-07-05 1992-01-23 Akzo N.V. Receptor directed-toxin conjugates
FR2666898A1 (fr) * 1990-09-18 1992-03-20 Toledano Jacques Dispositif et procede de dosage rapide de recepteurs membranaires ou de leurs ligands.
US6072039A (en) * 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
US5635597A (en) * 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
FR2764988B1 (fr) * 1997-06-20 1999-07-23 Bio Merieux Compose conjugue, reactif et kit le contenant, et utilisations dans un procede de fixation d'un materiel biologique
EP1489100B1 (de) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimäre Fusionsproteine zur Verwendung für gezielte Immuntherapie und allgemeine Immunerregung
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
EP1228214A2 (de) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietinformen mit verbesserten eigenschaften
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
DE60129695T2 (de) 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PT1383785E (pt) 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
JP4225196B2 (ja) 2001-07-03 2009-02-18 株式会社ジェイ・エム・エス 簡便な制御手段を有する血液透析装置
FR2832508A1 (fr) * 2001-11-21 2003-05-23 Bio Merieux Procede d'obtention d'une phase de capture et d'une phase de detection d'un materiel biologique cible et utilisation dans des tests elisa
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
EP2573166B1 (de) 2004-02-26 2016-05-11 Immunovative Therapies, Ltd. Verfahren zur Herstellung von T-Zellen zur Zelltherapie
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
CN100391726C (zh) * 2006-04-28 2008-06-04 江阴市万事达液压机械有限公司 缸体破碎机
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
WO2012151266A1 (en) 2011-05-03 2012-11-08 Michael Har-Noy Methods for handling biological drugs containing living cells
WO2012151279A2 (en) 2011-05-03 2012-11-08 Michael Har-Noy Induction of il-12 using immunotherapy
AU2019301697A1 (en) * 2018-07-13 2021-01-07 Il-2Rx, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide

Also Published As

Publication number Publication date
DK673788A (da) 1989-06-05
AU2635088A (en) 1989-06-08
FI885628A0 (fi) 1988-12-02
EP0319012A3 (de) 1990-05-16
HUT50506A (en) 1990-02-28
NO885389L (no) 1989-06-05
FI885628L (fi) 1989-06-05
KR890009978A (ko) 1989-08-05
EP0319012A2 (de) 1989-06-07
IL88565A0 (en) 1989-07-31
DK673788D0 (da) 1988-12-02
JPH02300A (ja) 1990-01-05
NO885389D0 (no) 1988-12-02
FI885628A7 (fi) 1989-06-05
PT89121A (pt) 1989-12-29

Similar Documents

Publication Publication Date Title
ZA888978B (en) Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension
EP0188920A3 (en) Interleukin 1 and its derivative
IL86378A0 (en) Phosphinothricin-resistant gene
GB8724618D0 (en) Micropipette
EG19726A (en) Molluscicides
GB8816850D0 (en) Recording materials
JPS6456668A (en) Novel pyrazineamide compound and manufacture
JPS6419050A (en) Chemical intermediate and manufacture
ZA889438B (en) N-hydroxy-5-phenyl-2 furancarboximidamides useful
PL270562A1 (en) Insecticidal and saprophyticidal specific
IE883606L (en) Immobilized interleukin 2
CS867987A1 (en) Zpusob pripravy 1 isokyanato 4 ehlorbenzenu
PL263661A1 (en) Can
HUT57654A (en) Writing materials
JPS6425789A (en) Substituted amidephophonate and amidephosphate
CA57949S (en) Support boucle-d'oreille
CS306087A1 (en) Zpusob enzymove vyroby 6 aminopenicilanove kyseliny z fenoxymethylpenicilinu stabilizovanymi bunkami kvasinek
CS92687A1 (en) 2alkyltio 6 formamidobenzotiazoly
CS266487A1 (en) Zpusob pripravy 4 jodanilinu
CS339587A1 (en) Thienotricyklicke 4 substituovane 1 methyltetrahydrothio pyraniumjodidy
CS330887A1 (en) Triglyceridy 2 arylpropionovych kyselin
CS262187A1 (en) Tricyklicke 4 substituovane 1 methyltetra hydrothiopyraniumjodidy
CS26787A1 (en) Sposob pripravy vysokocisteho 2 propanolu
CS26687A1 (en) Sposob pripravy vysokocisteho 2 propanolu
CS806887A1 (en) 11 11 87